HITIQ Reports $6.1 Million Loss with 21% Revenue Drop
HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.
- Revenue declined 21% to $1.59 million
- Net loss narrowed 15% to $6.1 million
- Commercial rollout of PROTEQT™ expanded nationally
- Secured strategic partnerships including Sportscover insurance integration
- Material uncertainty on going concern due to net liabilities
Revenue Decline and Loss Reduction Reflect Transition Phase
HITIQ Limited (ASX:HIQ) reported a 21% fall in revenues to $1.59 million for the year ended 30 June 2026, alongside a 15.4% reduction in net loss to $6.1 million. While the company remains unprofitable, the narrowing loss points to progress amid a challenging commercial environment. The decline in revenue was driven by a combination of slower-than-expected market adoption and regulatory delays in international markets, as detailed in the annual report.
PROTEQT™ Commercialisation Gains Traction
The company accelerated the commercial rollout of its concussion management platform PROTEQT™, securing national retail distribution through Rebel and expanding into research, defence, and insurance sectors. Notably, HITIQ entered a world-first partnership with Sportscover to embed head impact monitoring data into sports insurance underwriting and claims processes, opening a novel revenue channel. This integration marks a significant milestone in embedding objective concussion data into insurance products.
Scientific validation remained a cornerstone of HITIQ's strategy, with PROTEQT™ selected for inclusion in Australian Research Council-funded programs and collaborations with universities and sporting bodies. The company's instrumented mouthguard technology was deployed in a blinded pilot project with the Australian Sports Commission's The Park program, reinforcing the value of objective data in athlete brain health monitoring.
Funding and Balance Sheet Management Amid Scaling
FY26 was marked by ongoing investment to scale manufacturing and commercial capabilities, supported by milestone-based grants from the Victorian Government. HITIQ expanded its engineering and manufacturing footprint in Victoria, laying groundwork for future growth. However, these efforts came with increased funding demands.
The company raised capital through multiple share placements and convertible note conversions, including a $1.4 million private placement in July 2026 and subsequent convertible note conversions by major shareholder Harmil Angel Investments. Despite these efforts, HITIQ reported net liabilities of $6.3 million and a current liabilities excess over current assets of $6.5 million at year-end, prompting the auditor to highlight material uncertainty about the company's ability to continue as a going concern.
Governance and Leadership Changes
Governance saw notable changes with the appointment of Tony Toohey as a Non-Executive Director in October 2025, bringing extensive experience in gaming and technology sectors, and the resignation of Jennifer Tucker in July 2026. Executive Chair Earl Eddings, with a background in sports governance, continues to steer the company through its commercial transition.
Outlook Hinges on Commercial Conversion and Funding
Looking ahead, HITIQ aims to convert validation and pilot programs into sustained commercial revenue, focusing on recurring income streams across defence, insurance, retail, and research markets. The company plans to leverage its expanded manufacturing base and strategic partnerships to scale operations globally.
However, the path remains uncertain. The company’s ability to secure further funding, navigate regulatory requirements, and accelerate market adoption will be critical to overcoming the material uncertainty flagged in the audit report. Upcoming shareholder meetings and capital raising outcomes will be key milestones to watch as HITIQ seeks to solidify its financial footing.
Bottom Line?
HITIQ's progress in commercialising PROTEQT™ is tangible but overshadowed by funding pressures and a material going concern risk, making upcoming capital raises and market adoption critical.
Questions in the middle?
- Can HITIQ convert scientific validation into sustained, scalable revenue streams?
- How will ongoing regulatory and manufacturing challenges impact HITIQ's commercial rollout timelines?
- What are the prospects and terms for future funding rounds to alleviate the going concern uncertainty?
